CMD is taking the next step in the evolution of its αBET™ endotoxin testing system, moving from long-term planning to practical delivery. The focus is simple: make endotoxin testing easier to scale, without making day-to-day lab work more complicated.
A key development for 2026 is the launch of the αBET™ EM Expansion Module. Connecting directly to the existing αBET™ Master system, it doubles the testing capacity, by allowing two tests to run at the same time. Importantly, it does this without changing the workflow in your laboratories that you already know and trust.
Because the expansion is a modular add-on, labs can increase throughput when they need to, without replacing equipment or rethinking established processes. It’s a straightforward way to grow capacity while keeping testing reliable and familiar.
With continued investment and development planned, CMD will roll out further updates to the αBET™ platform during 2026, adding new capabilities step by step to support changing regulatory and operational needs.
Click here to book a demo onsite or remotely with our team
Understand the key benefits and features by reading more here
Get in touch with us here to ask any questions and gain a price